## Andrey I Tchorbanov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6779493/publications.pdf

Version: 2024-02-01

45 papers 600 citations

567281 15 h-index 23 g-index

45 all docs

45 docs citations

45 times ranked

737 citing authors

#	Article	IF	CITATIONS
1	Antitumor Properties of Epitope-Specific Engineered Vaccine in Murine Model of Melanoma. Marine Drugs, 2022, 20, 392.	4.6	O
2	Efficacy and safety of Aviron Rapid® in 18-60-year-old patients with clinical diagnosis of acute respiratory viral infection: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Folia Medica, 2021, 63, 129-137.	0.5	1
3	Simultaneous determination of ochratoxin A and enterotoxin A in milk by magnetic nanoparticles based fluorescent immunoassay. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2021, 38, 1218-1236.	2.3	5
4	Morphometric and Nanomechanical Features of Platelets from Women with Early Pregnancy Loss Provide New Evidence of the Impact of Inherited Thrombophilia. International Journal of Molecular Sciences, 2021, 22, 7778.	4.1	3
5	Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis. Briefings in Bioinformatics, 2021, 22, .	6.5	19
6	Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus. Archivum Immunologiae Et Therapiae Experimentalis, 2021, 69, 19.	2.3	O
7	Defective oogenesis in mice with pristane-induced model of systemic lupus. Journal of Reproductive Immunology, 2021, 148, 103370.	1.9	1
8	Suppression of autoreactive T and B lymphocytes by anti-annexin A1 antibody in a humanized NSG murine model of systemic lupus erythematosus. Clinical and Experimental Immunology, 2020, 199, 278-293.	2.6	18
9	Monoclonal antibody therapy that targets phospholipidâ€binding protein delays lupus activity in MRL/lpr mice. Scandinavian Journal of Immunology, 2020, 92, e12915.	2.7	2
10	Intensive therapy with gastropodan hemocyanins increases their antitumor properties in murine model of colon carcinoma. International Immunopharmacology, 2020, 84, 106566.	3.8	5
11	Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). International Journal of Molecular Medicine, 2020, 46, 903-912.	4.0	73
12	Design of Multi-Epitope Vaccine against SARS-CoV-2. Cybernetics and Information Technologies, 2020, 20, 185-193.	1.1	0
13	Immunoinformatic Analysis of Human Thyroglobulin. Cybernetics and Information Technologies, 2020, 20, 194-200.	1.1	0
14	Protein-engineered molecules carrying GAD65 epitopes and targeting CD35 selectively down-modulate disease-associated human B lymphocytes. Clinical and Experimental Immunology, 2019, 197, 329-340.	2.6	7
15	Targeting of Influenza Viral Epitopes to Antigen-Presenting Cells by Genetically Engineered Chimeric Molecules in a Humanized NOD <i>SCID</i> Gamma Transfer Model. Human Gene Therapy, 2018, 29, 1056-1070.	2.7	3
16	Bright green-emitting ds-DNA labeling employed by dicationic monomethine cyanine dyes: Apoptosis assay and fluorescent bio-imaging. Dyes and Pigments, 2018, 157, 267-277.	3.7	13
17	Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. Autoimmunity, 2017, 50, 257-268.	2.6	13
18	Cryopreservation and xenografting of human ovarian fragments: medulla decreases the phosphatidylserine translocation rate. Reproductive Biology and Endocrinology, 2016, 14, 79.	3.3	23

#	Article	IF	CITATIONS
19	Helix pomatia hemocyanin — A novel bio-adjuvant for viral and bacterial antigens. International Immunopharmacology, 2015, 26, 162-168.	3.8	16
20	The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner. Journal of Clinical Pathology, 2015, 68, 830-834.	2.0	14
21	Long-Time Cooling before Cryopreservation Decreased Translocation of Phosphatidylserine (Ptd-L-Ser) in Human Ovarian Tissue. PLoS ONE, 2015, 10, e0129108.	2.5	25
22	Serum or breast milk immunoglobulins mask the selfâ€reactivity of human natural IgG antibodies. Apmis, 2014, 122, 329-340.	2.0	2
23	Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma. BMC Immunology, 2014, 15, 34.	2.2	37
24	Suppression of allergen-specific B lymphocytes by chimeric protein-engineered antibodies. Immunobiology, 2014, 219, 45-52.	1.9	7
25	Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes. Immunologic Research, 2014, 60, 23-34.	2.9	2
26	Suppression of dsDNA-specific B lymphocytes reduces disease symptoms in SCID model of mouse lupus. Autoimmunity, 2014, 47, 162-172.	2.6	5
27	Generation of Gene-Engineered Chimeric DNA Molecules for Specific Therapy of Autoimmune Diseases. Human Gene Therapy Methods, 2012, 23, 357-365.	2.1	4
28	Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins. Fish and Shellfish Immunology, 2011, 30, 135-142.	3.6	18
29	Elimination of autoreactive B cells in humanized SCID mouse model of SLE. European Journal of Immunology, 2011, 41, 3301-3311.	2.9	18
30	New Biotechnologycal Approaches for Immunotherapy of Autoimmune Diseases. Biotechnology and Biotechnological Equipment, 2011, 25, 24-29.	1.3	0
31	Humanized SCID Mice Models of SLE. Current Pharmaceutical Design, 2011, 17, 1261-1266.	1.9	8
32	Re-establishing tolerance to DNA in humanized and murine models of SLE. Autoimmunity Reviews, 2010, 9, 499-502.	5.8	7
33	Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice. Rheumatology, 2010, 49, 2273-2280.	1.9	17
34	Intravenous immunoglobulin upâ€regulates the expression of the inhibitory FcγIIB receptor on B cells. Immunology and Cell Biology, 2009, 87, 529-533.	2.3	32
35	Simultaneous engagement of Fcγllb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Molecular Immunology, 2009, 47, 123-130.	2.2	15
36	An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes. Immunology Letters, 2008, 116, 168-173.	2.5	28

3

#	Article	IF	CITATION
37	Modulation of the immune response using Rapana thomasiana hemocyanin. International Immunopharmacology, 2008, 8, 1033-1038.	3.8	26
38	Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their FcÂllb receptor. International Immunology, 2008, 20, 165-175.	4.0	18
39	Selective silencing of DNAâ€specific B lymphocytes delays lupus activity in MRL/lpr mice. European Journal of Immunology, 2007, 37, 3587-3596.	2.9	34
40	Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus. Vaccine, 2006, 24, 1830-1837.	3.8	12
41	Serum IgM, IgG and IgA block by F(ab')2-dependent mechanism the binding of natural IgG autoantibodies from therapeutic immunoglobulin preparations to self-antigens. European Journal of Haematology, 2005, 74, 101-110.	2.2	9
42	Breaking of tolerance to native DNA in nonautoimmune mice by immunization with natural protein/DNA complexes. Lupus, 2005, 14, 543-550.	1.6	22
43	Molecular composition of diphtheria toxoid produced using semi-synthetic and meat extract-based broths. World Journal of Microbiology and Biotechnology, 2004, 20, 211-217.	3.6	2
44	Optimization of casein-based semisynthetic medium for growing of toxigenic Corinebacterium diphtheriae in a fermenter. Canadian Journal of Microbiology, 2004, 50, 821-826.	1.7	7
45	Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacology, 1999, 42, 159-165.	2.0	29